Articles related to TARGETED THERAPIES

This paring of PARP inhibitor and immune checkpoint inhibitor may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib with the anti CTLA-4 antibody ipilimumab achieved a 6-month PFS rate of 59.6%, which was superior to the comparator — a clinically meaningful benchmark of 44%. The results were not the same when a PD-1 inhibitor (nivolumab) were used. That trial arm yielded a poorer 6-month PFS vs the benchmark.

Guideline-directed binary distinctions between HER2-positive and HER2-negative breast cancer have guided physicians’ treatment decisions for quite some time, but new research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer, offering up a new nomenclature, HER2-low.

This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.

The IMpassion050 study was the first to assess the question: Can addition of atezolizumab to neoadjuvant standard of care (pertuzumab and trastuzumab [PH], and chemotherapy) improve outcomes in high-risk, HER2–positive early breast cancer? The results are a click away.

Dr. Christopher J. Hoimes, Associate Professor of Medicine-GU Oncology at Duke University, presents data on the KEYNOTE-045 Phase 3 Trial, which demonstrated that patients treated with KEYTRUDA (pembrolizumab) had a 27% reduction in risk of death compared to patients treated with chemotherapy.

HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Drs. Lyudmila Bazhenova and Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice in this 15-minute CME activity.